Barclays PLC Has $3.23 Million Holdings in Zymeworks Inc. (NYSE:ZYME)

Barclays PLC grew its stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 43.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 220,890 shares of the company's stock after acquiring an additional 66,506 shares during the period. Barclays PLC owned 0.32% of Zymeworks worth $3,234,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ZYME. Schroder Investment Management Group acquired a new stake in Zymeworks during the fourth quarter worth approximately $4,892,000. Assenagon Asset Management S.A. lifted its position in Zymeworks by 93.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock worth $9,403,000 after acquiring an additional 311,107 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new stake in Zymeworks during the fourth quarter worth approximately $3,368,000. Norges Bank acquired a new stake in Zymeworks during the fourth quarter worth approximately $2,953,000. Finally, Trexquant Investment LP bought a new position in shares of Zymeworks during the fourth quarter worth approximately $1,493,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zymeworks

In other news, Director Ecor1 Capital, Llc acquired 468,356 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average cost of $12.48 per share, with a total value of $5,845,082.88. Following the completion of the purchase, the director now directly owns 16,802,141 shares of the company's stock, valued at $209,690,719.68. The trade was a 2.87 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have bought 1,350,347 shares of company stock valued at $16,137,499 over the last three months. 1.92% of the stock is owned by insiders.

Analyst Ratings Changes

ZYME has been the topic of several recent research reports. HC Wainwright raised their target price on shares of Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Monday, March 10th. Lifesci Capital initiated coverage on shares of Zymeworks in a report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 target price on the stock. Finally, Citigroup raised their target price on shares of Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $21.00.

Zymeworks Price Performance

Shares of NYSE:ZYME opened at $12.88 on Tuesday. The company's 50 day simple moving average is $12.09 and its 200 day simple moving average is $13.52. The stock has a market capitalization of $896.15 million, a price-to-earnings ratio of -8.59 and a beta of 1.18. Zymeworks Inc. has a 1 year low of $8.21 and a 1 year high of $17.70.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

Want to see what other hedge funds are holding ZYME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zymeworks Inc. (NYSE:ZYME - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.